Clinical Trial Update: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 study of efatutazone dihydrochloride in patients with previously treated myxoid liposarcoma that cannot be removed surgically has completed. Results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liposarcoma
• Myxoid Liposarcoma

Drugs mentioned

• efatutazone dihydrochloride (efatutazone)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Liposarcoma | Phase 2 | Status: COMPLETED | Results posted: 2019-06-27